Skip to main content

Table 2 Chemotherapy administration and objective response

From: Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Induction therapy (n = 40)

Median cycle (range)

4

(1–4)

Maintenance therapy (n = 35)

Median cycle (range)

9

(1–54)

Response (n = 34)

CR

0 (0%)

PR

24 (70.6%)

SD

9 (26.5%)

PD

1 (2.9%)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us